NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes Imfinzi and Imjudo combination recommended as first-line treatment

#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp

Innovative treatment achieves complete long-term remission without surgery in 46 percent of advanced liver cancer patients – BioNews Central A study has shown that combined locoregional therapy and immunotherapy provides a safe, effective, and lasting treatment response for patients with advanced liver cancer, identifying key factors linked to complete response. ...

A study has shown that combined #LocoregionalTherapy and #immunotherapy provides a safe, effective, and lasting #TreatmentResponse for patients with #AdvancedLiverCancer, identifying key factors linked to #CompleteResponse.
#LiverCancer #LiverCancerTreatment #CombinationTherapy